TG Therapeutics Inc (TGTX) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Total Cash From Operating Activities Chart for TG Therapeutics Inc

TG Therapeutics Inc (TGTX) operating cash flow for FY2025 was USD -24.8M. TG Therapeutics Inc's operating cash flow moved from USD -4.0M in 1996 to USD -24.8M in 2025 over 29 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$8.29B
Implied Share Price
$54.17
Enterprise Value
$8.75B
Revenue (TTM)
$799.54M
EBITDA
$136.45M
Profit Margin
55.22%
Trailing P/E
19.70
Forward P/E
25.84
Price/Book (MRQ)
14.15
Price/Sales (TTM)
10.37
EV/EBITDA
62.77
EV/Revenue
10.94
Dividend Yield
—
Book Value
$4.26
Free Cash Flow (FY2025)
-$24.99M
Free Cash Flow Yield
-0.30%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.